ARDT · Ardent Health Partners, LLC

Ardent Health delivered strong Q1 2026 financial results, with total revenue reaching $1,602 million, a 7.0% year-over-year increase driven by 2.0% growth in adjusted admissions and 5.5% higher net patient service revenue per adjusted admission. Adjusted EBITDA surged 26.3% to $124 million, reflecting robust margin expansion from effective cost management, including significant improvements in supply chain and contract labor expenses under the IMPACT program, which is on track for $55 million in annual savings. Excluding a $10.9 million gain from an investment option, Adjusted EBITDA still grew 15% year-over-year. CEO Marty Bonick highlighted disciplined execution amid challenges like severe weather and a lighter respiratory season, which contributed to a 1.1% decline in admissions and 3.2% drop in emergency room visits, offset by 1.2% total surgery growth.

GAAP net income was $40 million or $0.28 per diluted share, slightly below prior year's $41 million or $0.29, but non-GAAP profitability strengthened significantly. Balance sheet remains solid with $610 million in cash and cash equivalents against $1.1 billion in debt, yielding a net leverage ratio of 1.0x and lease-adjusted net leverage of 2.6x, improved from 3.0x a year ago. Available liquidity stood at $0.9 billion. Operating cash flow was a use of $60 million, versus $25 million prior year, likely due to working capital timing.

The company reaffirmed its full-year 2026 guidance, signaling confidence in sustained performance despite evolving exchange market dynamics. Guidance includes total revenue of $6,400-$6,700 million, Adjusted EBITDA of $485-$535 million, adjusted admissions growth of 1.5%-2.5%, and diluted EPS of $0.90-$1.27. This reaffirmation, paired with Q1 outperformance, positions Ardent Health favorably for investors focused on operational leverage and healthcare volume recovery.